Quarterly Report • Aug 18, 2017
Quarterly Report
Open in ViewerOpens in native device viewer
(The figures in brackets and comparative figures in the text refer to the same period of last year. The comparative figures in the balance sheet refer to 31 December 2016.)
"Sales in the second quarter of 2017 reached SEK 156 million, which is an increase of 15% compared to the same period of last year. The strong second quarter, when sales to our important market Brazil gained new momentum, meant that for the first six months we achieved sales of SEK 297 million, a gross margin of 75% and an operating profit of SEK 115 million. We are on the right track and continue with the implementation of our strategic initiatives. I am also very pleased that in the quarter we established the subsidiary BioGaia Pharma AB to take advantage of the opportunities to develop drugs identified in the R&D activities conducted as part of our core business," says Axel Sjöblad, Managing Director of BioGaia AB.
Net sales amounted to SEK 156.0 million (136.0), an increase of 15% (excluding foreign exchange effects, 10%).
Net sales in the Pediatrics segment reached SEK 132.1 million (106.7), an increase of 24%.
Net sales in the Adult Health segment amounted to SEK 23.0 million (25.7), a decrease of 11%.
Operating profit was SEK 59.7 million (53.4), an increase of 12%.
Profit after tax was SEK 47.2 million (38.6), an increase of 22%.
Earnings per share totalled SEK 2.72 (2.22). No dilutive effects arose during the period.
The period's cash flow was SEK -117.3 million (-75.0).
Key events in the second quarter of 2017
BioGaia's oral health probiotic to be launched in three new markets.
BioGaia sets up subsidiary for the development of probiotic drugs.
Net sales amounted to SEK 297.2 million (269.9), an increase of 10% (excluding foreign exchange effects, 6%).
Net sales in the Pediatrics segment reached SEK 242.8 million (214.8), an increase of 13%.
Net sales in the Adult Health segment amounted to SEK 49.5 million (46.8), an increase of 6%.
Operating profit was SEK 115.5 million (104.7) 1) , an increase of 10%.
Profit after tax was SEK 90.1 million (77.3) 1) , an increase of 17%.
Earnings per share totalled SEK 5.20 (4.46) 1) . No dilutive effects arose during the period.
The period's cash flow was SEK -39.8 million (-35.4) 1) . Cash and cash equivalents at 30 June 2017 amounted to SEK 202.6 million (243.1).
1) Excluding the former subsidiary Infant Bacterial Therapeutics (IBT) AB, which was distributed to the shareholders in March 2016.
Teleconference: Investors, analysts and the media are invited to a teleconference 18 August 2017, at 9:30 a.m. CET. The presentation will be held by Managing Director Axel Sjöblad. To participate in the teleconference, please see telephone numbers at www.biogaia.com/investors/agenda/. The teleconference can also be followed at https://tv.streamfabriken.com/biogaia-q2-2017.
This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 18 August 2017 kl 8:00 a.m. CET.
The Board of Directors and the Managing Director of BioGaia AB hereby present the interim report for 1 January – 30 June 2017. A description of the company's operations is provided on page 13.
Sales for the second quarter of 2017 reached SEK 156 million (136), which was an increase of 15% compared to the same period of last year.
The sales increase was mainly due to strong development in the Asia Pacific and Americas regions. In Asia, sales were up by 13% and I am pleased that the positive trend in Japan and Hong Kong continues and that we are once again receiving orders from South Korea, although sales there have not yet met our expectations. Sales in the Americas increased by 74%. It was particularly satisfying to once again see strong performance in Brazil and continued good development in Canada.
Sales in EMEA rose by 1%. This modest increase was mainly driven by Eastern Europe and South Africa, which partly compensated for the weak sales to Italy. As previously mentioned, in Italy we are seeing the consequences of both inventory build-up and the merger of sales organizations following Recordati's acquisition of our earlier distributor Italchimici.
The Pediatrics segment grew by 24%, a positive trend driven by very strong sales of drops and continued growth in royalty revenue from Nestlé. In the Adult Health segment, our sales were down by 11%. This is not satisfactory and means that we are intensifying our efforts to find new distributions partners for our products in this segment.
The strong second quarter means that we after six months have achieved sales of SEK 297 million (an increase of 10% compared to the first half of last year) and a gross margin of 75% (71%). After the first half of the year, our operating expenses amounted to SEK 104 million. This is an increase by 17% compared to the same period of last year, and is mainly attributable to higher personnel, marketing and R&D expenses in line with our strategic plan. Operating profit rose by 10% to SEK 115 million, which resulted in an operating margin (EBIT) of 39% (39%).
BioGaia is on the right track and we continue with the implementation of our strategic initiatives. Internally, this means that we are moving forward with efforts to develop and strengthen our organization. Externally, this means that our roll-out of EasyDropper – our new drop package with improved dosing – is continuing and that we are seeking additional distribution partners for Prodentis and Gastrus. We are also working onward to expand our network of opinion-leaders and researchers and to increase our presence in our strategic markets.
In June we established our subsidiary BioGaia Pharma AB to take advantage of the opportunities to develop drugs identified in the R&D activities conducted as part of our core business, and which do not fit into the regulatory categories we normally use. We believe there is large potential to find interesting projects that can be further developed and then licensed to pharmaceutical companies.
Finally, I am delighted that we have signed three new exclusive agreements for Prodentis oral health lozenges; with Hansamed Ltd for sales in Canada, with BioCulture for sales in the Philippines, and with MTC Pharma Co Ltd for sales in Vietnam.
Consolidated net sales amounted to SEK 156.0 million (136.0) , which is an increase of SEK 20.0 million (15%) (excluding foreign exchange effects, 10%) compared to the second quarter of last year.
Sales were driven by growth in the Pediatrics segment, where sales in the quarter rose by 24% (excluding foreign exchange effects, 18%) to 132.1 million. This was mainly attributable to higher sales of drops (primarily to Brazil) and increased royalty revenue from Nestlé for the use of Lactobacillus reuteri in Growing Up Milk for children over the age of one year.
In the Adult Health segment, sales were down by 11% (excluding foreign exchange effects, -14%) to SEK 23.0 million. Growth in revenue from the new agreements in Japan was not sufficient to offset the drop in revenue from digestive tablets and oral health lozenges.
Other sales amounted to SEK 1.0 (3.6) million, a decrease of SEK 2.6 million that is explained by lower revenue from the collaboration agreement with Nestlé (for more information see below under "Other sales, January – June").
The total gross margin for the quarter was 75% (72%), an increase that was driven by the Pediatrics segment, where the gross margin reached 77% (73%). This is due to increased royalty revenue for the use of Lactobacillus reuteri in Growing Up Milk for children over the age of one year (with a 100% margin), higher sales of drops, and lower sales of bacteria cultures for infant formula with very low margins.
The gross margin for the Adult Health segment was 66% (63%). The increase is explained by revenue attributable to the new agreements in Japan.
Operating expenses rose by 18% compared to the second quarter of last year to SEK 56.0 million. This is mainly due to higher personnel expenses but also to increased costs for marketing activities and clinical studies.
Operating profit (EBIT) was SEK 59.7 million (53.4), up by 12% (excluding foreign exchange effects, 2 %). Operating margin was 38% (39%).
Profit after tax was SEK 47.2 million (38.6), an increase of SEK 8.6 million (23 %). The tax rate was 23% (26%).
Earnings per share amounted to SEK 2.72 (2.22). No dilutive effects arose during the period.
| Distributor/licensee | Country | Product |
|---|---|---|
| Abbott | Thailand | Drops and Protectis digestive health tablets with lemon flavor |
| Abbott | Mexico | Protectis digestive health tablets with lemon flavor |
| BioCulture | The Philippines | Prodentis oral health lozenges |
| Nestlé | Australia | Drops |
| Phillips Pharma | Kenya | Drops |
In April BioGaia announced the signing of three new exclusive agreements for Prodentis oral health lozenges, with Hansamed Ltd for sales in Canada, with BioCulture for sales in the Philippines and with MTC Pharma Co Ltd for sales in Vietnam. All three partners will sell Prodentis under the BioGaia brand. BioCulture launched in the second quarter and the other two companies plan to launch in the second half of 2017.
In June BioGaia announced that the company had established a subsidiary, BioGaia Pharma AB, to take advantage of the opportunities to develop drugs that are identified in the R&D activities conducted as part of the company's normal operations.
Since the foundation of BioGaia the company has focused its development efforts on the regulatory categories dietary supplements and food for special medical purposes. For certain target segments, these categories are limiting and in some cases BioGaia also lacks distribution channels for pipeline products. For this reason, the Board has decided to also develop probiotic drugs through BioGaia Pharma.
Drug candidates will primarily be developed to be licensed to appropriate partners at relatively early stages and BioGaia's capital commitment is therefore initially limited. If capital requirements were to increase significantly, the assessment is that external funding is possible.
Consolidated net sales amounted to SEK 297.2 million (269.9), which is an increase of SEK 27.3 million (10%) (excluding foreign exchange effects, 6%) compared to the same period of last year.
PEDIATRICS SEGMENT, JANUARY – JUNE
Net sales in BioGaia's core area Pediatrics amounted to SEK 242.8 (214.8) million, an increase of SEK 28.0 million (13%) (excluding foreign exchange effects, 9%). For the past rolling 12-month period, sales were up by 21% (excluding foreign exchange effects, 18%). This growth was driven mainly by higher sales of drops and increased royalty revenue from Nestlé for the use of Lactobacillus reuteri in Growing Up Milk for children older than one year.
Sales of drops, which make up the bulk of sales, rose primarily in the Americas and above all in Brazil, but also in Canada and Mexico. In Asia, sales of drops were unchanged. Sales in EMEA were down, which was attributable to Italy. As previously mentioned, our distributor there was acquired by Recordati, which has had a temporary negative impact on sales as a result of the earlier inventory build-up and the merger of sales organizations. For the past 12-month period, the positive sales trend for drops continued.
Royalty revenue from Nestlé for the use of Lactobacillus reuteri Protectis in Growing Up Milk for children older than one year rose sharply compared to the same period of last year and for the past 12 month period.
Sales of Protectis digestive health tablets were largely unchanged compared to the same period of last year. Tablet sales grew well in the EMEA, were unchanged in Asia Pacific and decreased in the Americas. For the past 12-month period, tablet sales showed good growth.
Sales of culture at low margins for use in infant formula declined compared to the same period of last year and for the past 12-month period, which is according to the plan from 2012 when Nestlé acquired the rights to this product and now produces the culture itself to a greater extent.
Royalty revenue from the collaboration agreement with Nestlé in the Pediatrics segment amounted to SEK 8.5 million (4.9). For more information, see below under "Other sales".
Net sales in the Adult Health segment amounted to SEK 49.5 million (46.8), an increase of 2.7 million (6%) (excluding foreign exchange effects, 3%). For the past rolling 12-month period, sales were up by 11% (excluding foreign exchange effects, 6%).
The increase in sales for Adult Health is mainly due to revenue attributable to the new agreements signed in December 2016 with Kabaya Ohayo Holding in Japan. The revenue consists partly of compensation for knowhow, education and preparations for the launch and, starting in the second quarter, also exclusivity fees that will be recognized successively over the term of the agreement. The entire exclusivity fee was paid at the beginning of 2017.
Sales of Protectis digestive health tablets decreased somewhat compared to the same period of last year. Sales were up in Asia Pacific but declined in EMEA (Italy and South Africa). In the Americas, Protectis digestive health tablets are not yet sold in the Adult Health segment but the launch is planned in Colombia. For the past 12-month period, tablet sales showed good development.
Sales of oral health products were down compared to the same period of last year. Sales rose in Asia Pacific but fell in other markets. Sales also decreased for the past 12-month period and the company is working actively to find additional distribution partners for the product.
Sales of Gastrus digestive health tablets remain very low and declined slightly in the first six months compared to the previous year. The company is working actively to find additional distribution partners for the product.
Other sales amounted to SEK 4.8 million (8.3), a decrease of SEK 3.5 million (42 %). No foreign exchange effects arose during the period.
Other sales include royalty revenue of SEK 3.5 million (7.0) from the collaboration agreement that was signed with Nestlé in March 2014. The royalty revenue amounts to a total of SEK 91.8 million for the period 2014-2017 and is distributed between the segments Pediatrics and New Business. Under the agreement, BioGaia has undertaken to carry out clinical studies on children and develop new products in new areas. BioGaia will recognize the royalty revenue in pace with completion of the projects. As of 30 June 2017, BioGaia had recognized revenue of SEK 75.9 million, of which SEK 42.2 million in other sales and SEK 33,7 million in the Pediatrics segment. The assessment is that the remaining revenue of SEK 15.9 million will be recognized during 2017 in the Pediatrics segment.
Starting with this interim report, sales are reported according to the geographic markets EMEA (Europa, Middle East, Africa), Asia Pacific (Asia, excluding Middle East, and Oceania) and the Americas (North and South America). Previously, sales were reported by geographic market according to the following regions: Europe, Asia, USA and Canada and Rest of the World.
Sales in EMEA amounted to SEK 192.3 million (196.2), a decrease of 2%. For the past 12-month period, sales rose by 14%.
Sales in Asia Pacific amounted to SEK 37.6 million (26.5), an increase of 42%. For the past 12-month period, sales were up by 33%.
In the Americas sales amounted to SEK 67.3 million (47.2), an increase of 43%. For the past 12-month period, sales declined by 20%.
THE BIOGAIA BRAND, JANUARY – JUNE
Of total finished consumer products, (drops, digestive health tablets, oral health lozenges, oral rehydration solution, etc.), 68% (57%) were sold under the BioGaia brand, including co-branding, in the first half of 2017.
Gross profit amounted to SEK 223.4 million (192.5), which is an increase of SEK 30.9 million (16%) compared to last year. The total gross margin was 75% (71%).
Gross margin for the Pediatrics segment was 76% (72%). This is due to higher royalty revenue for the use of bacteria culture in Growing Up Milk for children over the age of one year (with a 100% margin), increased sales of drops, and lower sales of cultures for infant formula with a very low margin.
Gross margin for the Adult Health segment was 69% (64%). The increase is due to the new agreements in Japan (see above under "Adult Health Segment").
Operating expenses (selling, administrative and R&D expenses) amounted to SEK 104.5 (89.6) 1) million, an increase of 17%. For the past 12-month period, operating expenses rose by 24%.
The increase is mainly attributable to higher R&D and selling expenses. This is due primarily to increased personnel and marketing expenses and higher costs for research projects and clinical studies.
Other operating expenses/income refer to exchange gains/losses on receivables and liabilities of an operating nature. These amounted to SEK -2.4 million (2.3).
Share in profit of associates refers to BioGaia's share of profit (36%) in Metabogen ABs and amounted to SEK -1.0 (-0.5) million.
Operating profit was SEK 115.5 (million 104.7) 1) , an increase of SEK 10.8 million (10%) (excluding foreign exchange effects, 3%). The operating margin was 39% (39%) 1) . For the past 12-month period, operating profit rose by 22%.
Profit before tax was SEK 117.1 million (102.8) 1) , an increase of SEK 14.3 million (14%). Net financial items include a foreign exchange gain/loss of SEK 1.8 (-3.1) million on forward exchange contracts. At 30 June 2017 the company had outstanding forward exchange contracts for EUR 13.9 million at an average exchange rate of SEK 9.55 and USD 5,6 million at an average exchange rate of SEK 8.75. The actual exchange gain/loss depends on the exchange rate on the maturity date of the contracts.
Profit after tax was SEK 90.1 million (77.3) 1) , an increase of SEK 12.8 million (16%). The tax rate for the Group was 23% (25%). Owing to the new distribution and license agreement that was signed in Japan at the end of 2016 (see annual report for 2016), a large share of the earlier loss carryforward in Japan will be utilized in the Japanese company. In the Group, the exclusivity fees will be recognized successively over the term of the agreement and a deferred tax asset was therefore recognized in 2016. At 30 June 2017 the deferred tax asset amounted to SEK 10.2 million. The Group thus has no loss carryforwards for which no deferred tax is recognized.
Earnings per share amounted to SEK 5.20 (4.46) 1) . No dilutive effects arose during the period.
Cash flow amounted to SEK -39.8 million (-35.4) 1) . This cash flow includes dividends of SEK 130.0 million (86.7) and investments of SEK 19.4 million (2.7) in property, plant and equipment (primarily at the production facility in Eslöv, where a new laboratory has been built). The cash flow also includes payment of exclusivity fees pertaining to the new license and distribution agreement in Japan that was signed in December 2016. These fees will be recognized successively over the term of the agreement. Cash and cash equivalents at 30 June 2017 amounted to SEK 202.6 million (243.1).
Investments in property, plant and equipment amounted to SEK 19.4 million (2.7), of which the majority refers to the subsidiary BioGaia Production (formerly TwoPac).
Investments in capitalized development expenditure amounted to SEK 0.0 million (0.0).
Net sales in the Parent Company amounted to SEK 290.6 million (262.7) and profit before tax was SEK 131.5 million (97.1). Cash flow in the Parent Company was SEK -34.8 million (-42.6).
Net sales in the wholly owned subsidiary in Japan reached SEK 13.6 million (10.3). Operating profit for the Japanese business was SEK 7.4 million (-0.5) (including revenue from Kabaya from the agreement signed at the end of 2016 – see above under "Revenue in the Adult Health segment").
BioGaia Production is a wholly owned subsidiary to BioGaia that manufactures and develops products, primarily drops, exclusively for BioGaia. Net sales amounted to SEK 40.1 million (35.1). Operating profit was SEK 12.9 million (9.0).
CapAble is owned 90.1% by BioGaia and 9.9% by CapAble's President. Net sales in CapAble amounted to SEK 1.0 million (0.0). Operating profit was SEK -0.5 million (-1.8).
The number of employees in the Group at 30 June 2017 was 115 (109).
Significant risks and uncertainties are described in the administration report of the annual report for 2016, on pages 40 and 41 and in Notes 29 and 30. No significant changes in these risks and uncertainties are assessed to have taken place at 30 June 2017.
This interim report has been prepared for the Group in accordance with IAS 34, Interim Financial Reporting, and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act. Disclosures in accordance with IAS 34 are provided in both notes and in other parts of this interim report.
The consolidated financial statements are presented in compliance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and the interpretations published by the IFRS Interpretations Committee that have been endorsed by the European Commission for application in the EU. Unless otherwise stated below, the accounting standards applied for the Group and the Parent Company are consistent with those used in preparation of the most recent annual report.
The Parent Company presents its financial statements in accordance with RFR 2, Accounting for Legal Entities, and the Annual Accounts Act, and applies the same accounting and valuation policies as in the most recent annual report.
The company applies IFRIC 17, which means that the distribution of the subsidiary IBT, in 2016, was reported at the fair value of the assets that have been distributed. The difference between the carrying amount of the net assets distributed and the carrying amount of the unpaid distribution at settlement was recognized in the income statement. The profit in the income statement for 2016 reflects the difference between the fair value (based on the average price of the share on the first day of trading on 29 March 2016) and the company's recorded value in the consolidated balance sheet on 18 March 2016.
The applied accounting policies correspond to those presented in the annual report for 2016. A number of new standards and interpretations have been published but are not yet effective.
Most of the company's sales are denominated in foreign currency, primarily EUR but also USD, CHF and JPY. With unchanged exchange rates compared to the same period of last year, net sales would have been SEK 10.5 million lower for the 6-month period and SEK 6.6 million lower for the quarter. Changes in foreign exchange rates affect both income and expenses. With unchanged exchange rates, operating profit for the period would have been SEK 7.9 lower (SEK 5.1 million for the quarter). Expenses arise mainly in SEK but also in JPY, EUR and USD.
BioGaia's goal is to create strong value growth and a good return for the shareholders. This will be achieved through a greater emphasis on the BioGaia brand, increased sales to both existing and new customers and a controlled cost level.
The long-term financial target is a sustainable operating margin (operating profit in relation to sales) of at least 34% with continued strong growth and increased investments in research, product development, brand building and the sales organization.
BioGaia's dividend policy is to pay a shareholder dividend equal to 40% of profit after tax.
In view of the company's strong portfolio consisting of an increased number of innovative products that are sold under the BioGaia brand to a growing extent, successful clinical trials and an expanding distribution network that covers a large share of the key markets, BioGaia's future outlook is bright.
1) Excluding the former subsidiary Infant Bacterial Therapeutics (IBT) AB which was distributed to the shareholders in March 2016.
| Consolidated statements of comprehensive income | |||
|---|---|---|---|
| ------------------------------------------------- | -- | -- | -- |
| (Amounts in SEK 000s) | Jan-Jun | Jan-Jun | April-Jun | April-Jun | Jan-Dec | Jul 2016- | Jul 2015- |
|---|---|---|---|---|---|---|---|
| 2017 | 2016 | 2017 | 2016 | 2016 | Jun 2017 | Jun 2016 | |
| Net sales | 297,179 | 269,897 | 156,046 | 136,044 | 534,696 | 561,978 | 480,272 |
| Cost of goods sold | -73,772 | -77,422 | -38,385 | -38,343 | -146,889 | -143,239 | -142,604 |
| Gross profit | 223,407 | 192,475 | 117,661 | 97,701 | 387,807 | 418,739 | 337,668 |
| Selling expenses | -59,132 | -49,561 | -32,300 | -26,450 | -108,108 | -117,679 | -94,417 |
| Administrative expenses | -10,878 | -10,727 | -6,043 | -5,138 | -20,893 | -21,044 | -19,606 |
| Research and development expenses | -34,467 | -29,287 | -17,648 | -15,666 | -63,795 | -68,975 | -53,238 |
| Shares of profit of associates | -1,000 | -523 | -500 | -290 | -1,184 | -1,661 | -588 |
| Other operating income/expenses | -2,443 | 2,325 | -1,505 | 3,248 | 5,610 | 842 | 3,037 |
| Operating profit | 115,487 | 104,702 | 59,665 | 53,405 | 199,437 | 210,222 | 172,856 |
| Interest income | - | 1,323 | - | 1,313 | 1,429 | 106 | 1,386 |
| Foreign exchange gains/losses, forward exchange contracts | 1,788 | -3,082 | 1,520 | -2,541 | -4,685 | 185 | -2,193 |
| Financial expenses | -130 | -120 | -19 | -85 | -122 | -132 | -216 |
| Profit before tax | 117,145 | 102,823 | 61,166 | 52,092 | 196,059 | 210,381 | 171,833 |
| Deferred tax | - | - | - | - | 10,433 | 10,433 | - |
| Tax expense | -27,079 | -25,511 | -13,986 | -13,525 | -47,143 | -48,711 | -43,610 |
| PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS |
90,066 | 77,312 | 47,180 | 38,567 | 159,349 | 172,103 | 128,223 |
| Discontinued operations (Distribution of IBT) PROFIT FOR THE PERIOD FROM DISCONTINUED OPERATIONS |
- | 67,935 | - | - | 67,935 | ||
| PROFIT FOR THE PERIOD | 90,066 | 145,247 | 47,180 | 38,567 | 227,284 | ||
| Items that may be reclassified subsequently to profit or loss | |||||||
| Gains/losses arising on translation of the financial | |||||||
| statements of foreign operations | 433 | 1,328 | 518 | 1,669 | 889 | ||
| Comprehensive income for the period | 90,499 | 146,575 | 47,698 | 40,236 | 228,173 | ||
| Profit for the period from continuing operations attributable | |||||||
| to: | |||||||
| Owners of the Parent Company | 90,066 | 77,312 | 47,180 | 38,567 | 159,349 | ||
| Non-controlling interests | 0 | 0 | 0 | 0 | 0 | ||
| 90,066 | 77,312 | 47,180 | 38,567 | 159,349 | |||
| Profit for the period attributable to: | |||||||
| Owners of the Parent Company | 90,066 | 145,531 | 47,180 | 38,567 | 227,568 | ||
| Non-controlling interests | 0 | -284 | 0 | 0 | -284 | ||
| 90,066 | 145,247 | 47,180 | 38,567 | 227,284 | |||
| Comprehensive income for the period attributable to: | |||||||
| Owners of the Parent Company | 90,499 | 146,859 | 47,698 | 40,236 | 228,457 | ||
| Non-controlling interests | 0 | -284 | 0 | 0 | -284 | ||
| 90,499 | 146,575 | 47,698 | 40,236 | 228,173 | |||
| Earnings per share | |||||||
| Earnings per share in continuing operations (average number of shares), SEK |
5,20 | 4,46 | 2,72 | 2,22 | 9,19 | ||
| Earnings per share including discontinued operations (average number of shares), SEK |
5.20 | 8.39 | 2.72 | 2.22 | 13.13 | ||
| Number of shares (thousands) | 17,336 | 17,336 | 17,336 | 17,336 | 17,336 | ||
| Average number of shares (thousands) | 17,336 | 17,336 | 17,336 | 17,336 | 17,336 |
| CONSOLIDATED STATEMENTS OF FINANCIAL | |||
|---|---|---|---|
| POSITION | 30 June | 30 June | 31 Dec |
| Summary (Amounts in SEK 000s) | 2017 | 2016 | 2016 |
| ASSETS | |||
| Property, plant and equipment | 99,075 | 83,230 | 82,430 |
| Investments in associates | 9,752 | 7,412 | 10,752 |
| Deferred tax asset | 10,220 | - | 10,433 |
| Other non-current receivables | 41 | 22 | 23 |
| Total non-current assets | 119,088 | 90,664 | 103,638 |
| Current assets excl. cash and cash equivalents | 157,793 | 173,350 | 142,271 |
| Cash and cash equivalents | 202,582 | 148,205 | 243,069 |
| Total current assets | 360,375 | 321,555 | 385,340 |
| TOTAL ASSETS | 479,463 | 412,219 | 488,978 |
| EQUITY AND LIABILITIES | |||
| Equity attributable to owners of the Parent Company | 375,672 | 333,600 | 415,198 |
| Non-controlling interests | -16 | -18 | -18 |
| Total equity | 375,656 | 333,582 | 415,180 |
| Provision for deferred tax | 332 | 351 | 332 |
| Interest-free current liabilities | 103,475 | 78,286 | 73,466 |
| TOTAL EQUITY AND LIABILITIES | 479,463 | 412,219 | 488,978 |
Current assets include forward exchange contracts with a fair value of SEK 1.5 million. All forward exchange contracts are attributable to level 2 of the fair value hierarchy.
| CONSOLIDATED CASH FLOW STATEMENTS |
Jan-June | Jan-June | April-June | April-June | Jan-Dec |
|---|---|---|---|---|---|
| Summary (Amounts in SEK 000s) | 2017 | 2016 | 2017 | 2016 | 2016 |
| Operating activities Operating profit (including discontinued operations) |
115,487 | 99,540 | 59,665 | 53,405 | 194,275 |
| Depreciation/amortization (non-cash) | 2,769 | 3,377 | 1,462 | 1,687 | 7,074 |
| Other non-cash items | 1,625 | -718 | 988 | -1,397 | -1,885 |
| Gains/losses on realized forward exchange | 119,881 | 102,199 | 62,115 | 53,695 | 199,464 |
| contracts | -1,166 | -587 | -575 | -297 | -2,081 |
| Paid tax | -24,774 | -24,709 | -12,387 | -12,386 | -43,381 |
| Interest received and paid | -131 | 1,200 | -20 | 1,226 | 1,305 |
| Cash flow from operating activities before changes in working capital |
93,810 | 78,103 | 49,133 | 42,238 | 155,307 |
| Changes in working capital | 15,828 | -30,889 | -23,678 | -29,381 | -7,378 |
| Cash flow from operating activities | 109,638 | 47,214 | 25,455 | 12,857 | 147,929 |
| Acquisition of property, plant and equipment | -19,432 | -2,674 | -12,779 | -1,179 | -5,611 |
| Acquisition of financial assets | - | - | - | - | -4,000 |
| Cash flow from investing activities | -19,432 | -2,674 | -12,779 | -1,179 | -9,611 |
| Dividends | -130,023 | -86,682 | -130,023 | -86,682 | -86,682 |
| Distribution of shares in IBT | - | -37,629 | - | - | -37,629 |
| Cash flow from financing activities | -130,023 | -124,311 | -130,023 | -86,682 | -124,311 |
| Cash flow for the period | -39,817 | -79,771 | -117,347 | -75,004 | 14,007 |
| Cash and cash equivalents at beginning of period Exchange difference in cash and cash |
243,069 | 226,882 | 320,617 | 221,494 | 226,882 |
| equivalents | -670 | 1,094 | -688 | 1,715 | 2,180 |
| Cash and cash equivalents at end of period |
202,582 | 148,205 | 202,582 | 148,205 | 243,069 |
| Pledged assets and contingent liabilities | GROUP | PARENT COMPANY | ||
|---|---|---|---|---|
| 30 June | 31 Dec | 30 June | 31 Dec | |
| 2017 | 2016 | 2017 | 2016 | |
| Floating charges | 2,000 | 2,000 | 2,000 | 2,000 |
| Blocked funds for construction in TwoPac AB | 253 | 253 | - | - |
| Total | 2,253 | 2,253 | 2,000 | 2,000 |
| Contingent liabilities | None | None | None | None |
| (Amounts in SEK 000s) | Jan-June | Jan-June | Jan-dec |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| At beginning of period | 415,180 | 395,833 | 395,833 |
| Dividends | -130,023 | -86,682 | -86,682 |
| Distribution of shares in IBT | - | -122,144 | -122,144 |
| Comprehensive income for the period | 90,499 | 146,575 | 228,173 |
| At end of period | 375,656 | 333,582 | 415,180 |
(Amounts in SEK 000s)
| April | April | July | |||||
|---|---|---|---|---|---|---|---|
| Jan-June | Jan-June | June | June | Jan-Dec | 2016- | July 2015- | |
| June | June | ||||||
| Revenue by segment | 2017 | 2016 | 2017 | 2016 | 2016 | 2017 | 2016 |
| Pediatrics | 242,842 | 214,785 | 132,063 | 106,729 | 433,028 | 461,085 | 380,289 |
| Adult Health | 49,527 | 46,827 | 23,022 | 25,731 | 85,274 | 87,974 | 79,437 |
| Other | 4,810 | 8,285 | 961 | 3,584 | 16,394 | 12,919 | 20,546 |
| Total | 297,179 | 269,897 | 156,046 | 136,044 | 534,696 | 561,978 | 480,272 |
| Jan-June | Jan-June | April June |
April June |
Jan-Dec | July 2016- |
July 2015- | |
| June | June | ||||||
| Gross profit by segment | 2017 | 2016 | 2017 | 2016 | 2016 | 2017 | 2016 |
| Pediatrics | 184,340 | 154,708 | 101,547 | 77,955 | 318,811 | 348,443 | 266,647 |
| Adult Health | 34,257 | 29,758 | 15,153 | 16,162 | 52,917 | 57,416 | 51,252 |
| Other | 4,810 | 8,009 | 961 | 3,584 | 16,079 | 12,880 | 19,769 |
| Jan-June | Jan-June | April June |
April June |
Jan-Dec | July 2016- June |
July 2015- June |
|
|---|---|---|---|---|---|---|---|
| Revenue by geographic market | 2017 | 2016 | 2017 | 2016 | 2016 | 2017 | 2016 |
| Asia Pacific | 37,651 | 26,479 | 16,051 | 14,293 | 55,550 | 66,722 | 50,124 |
| EMEA | 192,246 | 196,179 | 98,148 | 97,643 | 376,439 | 372,506 | 328,035 |
| Americas (North and South America) | 67,282 | 47,239 | 41,847 | 24,108 | 102,707 | 122,750 | 102,113 |
| Total | 297,179 | 269,897 | 156,046 | 136,044 | 534,696 | 561,978 | 480,272 |
| Profit from discontinued operations (distribution) | Jan-June | Jan-June |
|---|---|---|
| (Amounts in SEK 000s) | 2017 | 2016 |
| Net sales Selling expenses Research and development expenses Other operating income/expenses |
- - - - |
- - -5,101 -61 |
| Operating profit Financial expenses Difference between fair value of IBT's shares and the carrying amount Profit for the period before tax |
- - - - |
-5,162 -2 73,099 67,935 |
| Tax relief due to group contributions Profit for the period after tax |
- - |
- 67,935 |
| Cash flow from discontinued operations | Jan-June | Jan-June |
|---|---|---|
| (Amounts in SEK 000s) | 2017 | 2016 |
| Operating activities Investing activities |
- - |
-6,781 - |
| Total cash flow | - | -6,781 |
The presented key ratios are central for understanding and evaluating BioGaia's operations and financial position.
| Jan June |
Jan June |
Jan-Dec | |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| Net sales, SEK 000s | 297,179 | 269,897 | 534,696 |
| Operating profit, SEK 000s 1) | 115,487 | 104,702 | 199,437 |
| Profit after tax, SEK 000s 1) | 90,066 | 77,312 | 159,349 |
| Return on | |||
| - average equity1) | 23% | 21% | 39% |
| - average capital employed 1) | 30% | 29% | 49% |
| Capital employed, SEK 000s | 375,988 | 333,933 | 415,512 |
| Number of shares, thousands 2) | 17,336 | 17,336 | 17,336 |
| Average number of shares, thousands | 17,336 | 17,336 | 17,336 |
| Earnings per share in continuing operations, SEK 1) | 4.46 | 9.19 | |
| Earnings per share. SEK 3) | 5.20 | 8.39 | 13.13 |
| Diluted earnings per share. SEK | 5.20 | 8.39 | 13.13 |
| Equity per share. SEK | 21.67 | 19.24 | 23.95 |
| Diluted equity per share. SEK | 21.67 | 19.24 | 23.95 |
| Equity/assets ratio | 78% | 81% | 85% |
| Operating margin 1) | 39% | 39% | 37% |
| Profit margin 1) | 39% | 38% | 37% |
| Average number of employees 1) | 113 | 102 | 107 |
1) The figures for 2016 do not include discontinued operations (distribution of IBT)
2) No dilutive effect arose during the period
3) Key ratio defined according to IFRS
The company presents certain financial ratios in the interim report that are not defined according to IFRS. The company is of the opinion that these performance measures provide valuable supplementary information to investors and the company's management since they enable evaluation and benchmarking of the company's performance. Since not all companies calculate financial ratios in the same manner. these are not always comparable to the performance measures used by other companies. Consequently. these financial ratios should not be seen as a replacement for performance measures that are defined according to IFRS. The following key ratios are not defined according to IFRS unless otherwise stated.
Average number of shares: Weighted average number of shares during a certain period.
Capital employed: Total assets less interest-free liabilities. Earnings per share: Profit attributable to owners of the Parent Company divided by the average number of shares (definition according to IFRS).
Earnings per share in continuing operations: Profit from continuing operations attributable to owners of the Parent Company divided by the average number of shares.
Equity/assets ratio: Shareholders' equity divided by total assets.
Equity per share: Shareholders' equity attributable to the owners of the Parent Company divided by the number of shares.
Growth: Sales for the current year less sales for the previous year divided by sales for the previous year.
Net financial items: The result from financial income and financial expenses.
Operating margin: Operating profit in relation to net sales. Operating profit: Sales less cost of goods sold. selling expenses. administrative expenses. R&D expenses and other operating expenses plus other operating income.
Profit margin: Profit before tax in relation to net sales.
Return on capital employed: Profit before financial items plus financial income divided by average capital employed.
Return on equity: Profit attributable to the owners of the Parent Company divided by average shareholders' equity attributable to the owners of the Parent Company.
Reconciliation against IFRS
| Jan-June | Jan-June | Jan-Dec | |
|---|---|---|---|
| Return on capital employed | 2017 | 2016 | 2016 |
| Operating profit | 115,487 | 104,702 | 199,437 |
| Financial income | 1,788 | 1,323 | 1,429 |
| Profit before financial items plus financial income | 117,275 | 106,025 | 200,866 |
| Total assets | 479,463 | 412,219 | 488,978 |
| Interest-free liabilities | -103,475 | -78,286 | -73,466 |
| Capital employed | 375,988 | 333,933 | 415,512 |
| Average capital employed | 395,750 | 365,059 | 405,848 |
| Return on capital employed | 30% | 29% | 49% |
| Jan-June | Jan-June | Jan-Dec | |
| Return on equity | 2017 | 2016 | 2016 |
| Profit attributable to owners of the Parent Company | 90,066 | 77,312 | 159,349 |
| Equity attributable to owners of the Parent Company | 375,672 | 333,600 | 415,198 |
| Average equity attributable to owners of the Parent Company | 395,435 | 364,726 | 405,525 |
| Return on equity | 23% | 21% | 39% |
| Pediatrics | Adult Health | Other | Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan June |
April June |
Jan June |
April June |
Jan June |
April June |
Jan-June | April June |
|||||||||
| 2017 | % | 2017 | % | 2017 | % | 2017 | % | 2017 | % | 2017 | % | 2017 | % | 2017 | % | |
| Change in sales by segment | ||||||||||||||||
| Organic growth | 18,820 | 9% | 19,594 | 18% | 1,435 | 3% | -3,583 | -14% | -3,475 | -42% | -2,623 | -73% | 16,780 | 6% | 13,388 | 10% |
| Foreign exchange effects Reported change |
9,237 28,057 |
4% 13% |
5,740 25,334 |
5% 24% |
1,265 2,700 |
3% 6% |
874 -2,709 |
3% -11% |
- -3,475 |
-42% | - -2,623 |
-13% | 10,502 27,282 |
3% 10% |
6,614 20,002 |
5% 15% |
Foreign exchange effects reflect the foreign currency changes for the period compared with the same period of last year,
| PARENT COMPANY INCOME STATEMENTS | Jan-June | Jan-June | Jan-Dec |
|---|---|---|---|
| (Amounts in SEK 000s) | 2017 | 2016 | 2016 |
| Net sales | 290,573 | 262,715 | 518,307 |
| Cost of goods sold | -89,232 | -86,424 | -164,201 |
| Gross profit | 201,341 | 176,291 | 354,106 |
| Selling expenses | -48,113 | -40,931 | -90,308 |
| Administrative expenses | -10,003 | -9,813 | -19,119 |
| Research and development expenses | -34,575 | -29,303 | -64,203 |
| Other operating income | -2,438 | 2,320 | 6,002 |
| Operating profit | 106,212 | 98,564 | 186,478 |
| Impairment loss on shares in subsidiary | - | - | -3,578 |
| Reversal of receivable from subsidiary | 23,351 | - | - |
| Net financial items | 1,939 | -1,503 | -2,791 |
| Profit before tax | 131,502 | 97,061 | 180,109 |
| Tax expense | -23,924 | -23,687 | -43,156 |
| PROFIT FOR THE PERIOD | 107,578 | 73,374 | 136,953 |
| PARENT COMPANY BALANCE SHEETS | 30 June | 30 June | 31 Dec |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| ASSETS | |||
| Property, plant and equipment | 1,220 | 629 | 694 |
| Shares in group companies | 51,181 | 51,132 | 51,133 |
| Shares in associates | 12,001 | 8,000 | 12,000 |
| Non-current receivables from subsidiaries | 55,835 | 55,835 | 55,835 |
| Total non-current assets | 120,237 | 115,596 | 119,662 |
| Current assets excl, cash and cash equivalents | 136,788 | 156,236 | 131,954 |
| Cash and cash equivalents | 180,410 | 131,279 | 215,880 |
| Total current assets | 317,198 | 287,515 | 347,834 |
| TOTAL ASSETS | 437,435 | 403,111 | 467,496 |
| EQUITY AND LIABILITIES | |||
| Equity | 356,589 | 315,455 | 379,034 |
| Interest-free current liabilities | 80,846 | 87,656 | 88,462 |
| TOTAL EQUITY AND LIABILITIES | 437,435 | 403,111 | 467,496 |
| PARENT COMPANY CASH FLOW STATEMENTS | Jan-June | Jan-Dec | |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| Operating activities | |||
| Operating profit | 106,212 | 98,564 | 186,478 |
| Depreciation | 209 | 232 | 449 |
| Other non-cash items | 624 | -775 | -1,944 |
| Gain/losses on realized foreign exchange contracts | -1,166 | -587 | -2,082 |
| Paid tax | -23,349 | -23,249 | -40,637 |
| Interest received and paid | 152 | 1,579 | 1,895 |
| Cash flow from operating activities before changes in working capital | 82,682 | 75,764 | 144,159 |
| Changes in working capital | -10,072 | -31,655 | -12,333 |
| Cash flow from operating activities | 72,610 | 44,109 | 131,826 |
| Acquisition of property, plant and equipment | -735 | - | -283 |
| Acquisition of financial assets | -49 | - | -4,000 |
| Repayment of loan to subsidiary | 23,352 | - | - |
| Cash flow from investing activities | 22,568 | 0 | -4,283 |
| Dividends | -130,023 | -86,682 | -86,682 |
| Cash flow from financing activities | -130,023 | -86,682 | -86,682 |
| Cash flow for the period | -34,845 | -42,573 | 40,861 |
| Cash and cash equivalents at beginning of period | 215,880 | 173,077 | 173,077 |
| Exchange difference in cash and cash equivalents | -625 | 775 | 1,942 |
| Cash and cash equivalents at end of period | 180,410 | 131,279 | 215,880 |
| (Amounts in SEK 000s) | Jan-June | Jan-June | Jan-Dec |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| At beginning of year | 379,034 | 410,569 | 410,569 |
| Distribution of shares in IBT | - | -81,806 | -81,806 |
| Dividends | -130,023 | -86,682 | -86,682 |
| Profit for the period | 107,578 | 73,374 | 136,953 |
| At end of period | 356,589 | 315,455 | 379,034 |
The Parent Company holds 100% of the shares in BioGaia Biologics Inc, USA, BioGaia Japan Inc, BioGaia Production AB (formerly TwoPac AB) and Tripac AB,
The Parent Company also holds 90.1 % of the shares in CapAble AB and 96% of the shares in BioGaia Pharma AB,
Annwall & Rothschild Investment AB holds 740,668 class A shares and 759,332 class B shares, which is equal to 8.7% of the share capital and 34.1% of the votes in BioGaia AB, Annwall & Rothschild Investment AB is owned by Peter Rothschild, Group President of BioGaia, and Jan Annwall, a member of the Board of BioGaia AB. The only transaction that took place during the period was a dividend of SEK 7.50 per share,
| 18 August 2017 | Teleconference at 9:30 a.m, with Managing Director Axel Sjöblad. To take part in the conference, please see |
|---|---|
| www.biogaia.com/investors/agenda for telephone numbers. The teleconference can also be followed at | |
| https://tv,streamfabriken,com/biogaia-q2-2017, | |
| 25 October 2017 | Interim management statement, 1 January – 30 September 2017 |
| 8 February 2018 Year-end report 2017 | |
| 25 April 2018 | Interim management statement, 1 January – 31 March 2018 |
| 17 August 2018 | Interim report 1 January – 30 June 2018 |
The Board of Directors and the Managing Director hereby give their assurance that the interim report provides a true and fair picture of the business activities, financial position and results of operations of the Parent Company and the Group, and describes the significant risks and uncertainties to which the Parent Company and the Group companies are exposed.
Stockholm, 18 August 2017
| David Dangoor | Jan Annwall | Ewa Björling |
|---|---|---|
| Board Chairman | Board member | Board member |
| Stefan Elving | Margaretha Gadnell | Inger Holmström |
| Board member | Board member | Board member |
| Anthon Jahreskog | Brit Stakston | Axel Sjöblad |
| Board member | Board member | Managing Director |
We have reviewed the accompanying condensed interim financial statements of BioGaia AB (publ) at 30 June 2017 and for the twelvemonth period then ended. The Board of Directors and Managing Director are responsible for the preparation and fair presentation of this interim financial information in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim financial information based on our review,
We conducted our review in accordance with the Standard on Review Engagements ISRE 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures, A review is substantially less in scope than an audit conducted in accordance with ISA (International Standards on Auditing) and other generally accepted auditing practices. The procedures performed in a review do not enable us to obtain a level of assurance that would make us aware of all significant matters that might be identified in an audit. Therefore, the conclusion expressed based on a review does not give the same level of assurance as a conclusion based on an audit.
Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim financial information does not, in all material aspects, give a true and fair view of the financial position of the Group in accordance with IAS 34 and the Swedish Annual Accounts Act and of the Parent Company in accordance with the Swedish Annual Accounts Act.
Stockholm, 18 August 2017
Deloitte AB
Birgitta Lööf Authorized Public Accountant
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Lactobacillus reuteri (Reuteri) in combination with unique packaging solutions that make it possible to create probiotic products with a long shelf life,
The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of Nasdaq OMX Nordic Exchange Stockholm.
BioGaia has 115 employees, of whom 104 are based in Sweden (Stockholm, Lund and Eslöv), two in the USA and nine in Japan.
BioGaia's revenue comes mainly from the sale of drops, digestive health tablets, oral rehydration solution (ORS) and oral health products to distributors, but also of revenue from the sale of bacteria cultures to be used in licensee products (such as infant formula and dairy products), as well as royalty revenue for the use of Lactobacillus reuteri in licensee products and sales of delivery systems such as straws and caps.
The products are sold through nutrition and pharmaceutical companies in some 90 countries worldwide.
BioGaia holds patents for the use of Lactobacillus reuteri and certain packaging solutions in all major markets.
At the beginning of 2006 BioGaia launched its own consumer brand and today there are a number of distribution partners that sell finished products under the BioGaia brand in a large number of markets. One central part of BioGaia's strategy is to increase the share of sales consisting of BioGaia-branded products.
Some of BioGaia's distributors sell finished consumer products under their own brand names. On these products, the BioGaia brand is shown on the consumer package since BioGaia is both the manufacturer and licensor.
BioGaia's licensees add Reuteri culture to their products and sell these under their own brand names. On these products, the BioGaia brand is most often shown on the package as the licensor/patent holder.
BioGaia's strains of Lactobacillus reuteri are some of the world's most well researched probiotics, especially in young children. To date, 173 clinical studies using BioGaia's human strains of Lactobacillus reuteri have been performed on around 14,800 individuals of all ages. The results have been published in 146 articles in scientific journals.
Studies have been performed on:
| 2017-06-21 | BioGaia sets up subsidiary for development of probiotic drugs |
|---|---|
| 2017-05-04 | Annual General Meeting of BioGaia |
| 2017-05-03 | BioGaia AB – Interim management statement 1 January – 31 March 2017 |
BioGaia AB Box 3242, SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A, Stockholm Telephone: +46 8-555 293 00, Corp, identity no, 556380-8723 www.biogaia.com For additional information, contact: Axel Sjöblad, Managing Director, BioGaia AB, tel +46 8-555 293 00 Margareta Hagman, Executive Vice President, BioGaia AB, telephone +46 8-555 293 00
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.